Overview

Keeping RAASi Treatment With Optimal Potassium Control

Status:
RECRUITING

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).

Phase:

PHASE3

Details

Lead Sponsor:

Fundación para la Investigación del Hospital Clínico de Valencia

Treatments:

sodium zirconium cyclosilicate